These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26713307)

  • 1. Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea.
    Lee SH; Gong HS; Kim TH; Park SY; Shin JH; Cho SW; Byun DW
    J Bone Metab; 2015 Nov; 22(4):167-74. PubMed ID: 26713307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.
    McClung M; Harris ST; Miller PD; Bauer DC; Davison KS; Dian L; Hanley DA; Kendler DL; Yuen CK; Lewiecki EM
    Am J Med; 2013 Jan; 126(1):13-20. PubMed ID: 23177553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate drug holiday: choosing appropriate candidates.
    Ro C; Cooper O
    Curr Osteoporos Rep; 2013 Mar; 11(1):45-51. PubMed ID: 23296595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate drug holiday: who, when and how long.
    Diab DL; Watts NB
    Ther Adv Musculoskelet Dis; 2013 Jun; 5(3):107-11. PubMed ID: 23858334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
    Anagnostis P; Paschou SA; Mintziori G; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; Senturk LM; Simoncini T; Stevenson JC; Stute P; Trémollieres FA; Goulis DG
    Maturitas; 2017 Jul; 101():23-30. PubMed ID: 28539165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate Drug Holidays: Evidence From Clinical Trials and Real-World Studies.
    Wang M; Wu YF; Girgis CM
    JBMR Plus; 2022 Jun; 6(6):e10629. PubMed ID: 35720669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of drug holidays in women taking bisphosphonates.
    Diab DL; Watts NB
    Menopause; 2014 Feb; 21(2):195-7. PubMed ID: 23921518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate drug holidays--when, why and for how long?
    Anagnostis P; Stevenson JC
    Climacteric; 2015; 18 Suppl 2():32-8. PubMed ID: 26507608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study.
    Adams AL; Adams JL; Raebel MA; Tang BT; Kuntz JL; Vijayadeva V; McGlynn EA; Gozansky WS
    J Bone Miner Res; 2018 Jul; 33(7):1252-1259. PubMed ID: 29529334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates in the treatment of osteoporosis: a review of skeletal safety concerns.
    Habib ZA
    Expert Rev Endocrinol Metab; 2017 Jan; 12(1):59-71. PubMed ID: 30058876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical femur fracture during bisphosphonate drug holiday: a case series.
    Lovy AJ; Koehler SM; Keswani A; Joseph D; Hasija R; Ghillani R
    Osteoporos Int; 2015 Jun; 26(6):1755-8. PubMed ID: 25832177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
    McClung M
    Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making.
    Hayes KN; Winter EM; Cadarette SM; Burden AM
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33803095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety issues with bisphosphonate therapy for osteoporosis.
    Suresh E; Pazianas M; Abrahamsen B
    Rheumatology (Oxford); 2014 Jan; 53(1):19-31. PubMed ID: 23838024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
    Adler RA; El-Hajj Fuleihan G; Bauer DC; Camacho PM; Clarke BL; Clines GA; Compston JE; Drake MT; Edwards BJ; Favus MJ; Greenspan SL; McKinney R; Pignolo RJ; Sellmeyer DE
    J Bone Miner Res; 2016 Jan; 31(1):16-35. PubMed ID: 26350171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological management of osteoporosis - when to treat and when to stop.
    Vannucci L; Brandi ML
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1315-1322. PubMed ID: 27322492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
    Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
    Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of bisphosphonates in older adults: how long is long enough?
    Dunn RL; Bird ML; Conway SE; Stratton MA
    Consult Pharm; 2013 Jan; 28(1):39-57. PubMed ID: 23315281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and risks of bisphosphonate therapy for osteoporosis.
    Khosla S; Bilezikian JP; Dempster DW; Lewiecki EM; Miller PD; Neer RM; Recker RR; Shane E; Shoback D; Potts JT
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2272-82. PubMed ID: 22523337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.